Keywords

Details

Category:

Articles

Type:

artykuły w czasopismach

Published in:

Antibiotics-Basel no. 9,
ISSN: 2079-6382

Language:

English

Publication year:

2020

Bibliographic description:

Mroczyńska M., Brillowska-Dąbrowska A.: Review on Current Status of Echinocandins Use// Antibiotics-Basel -Vol. 9,iss. 5 (2020), s.227-

DOI:

Digital Object Identifier (open in new tab) 10.3390/antibiotics9050227

Bibliography: test

1. Brown, G.D.; Denning, D.W.; Gow, N.A.R.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden killers: Human fungal infections. Sci. Transl. Med. 2012, 4, 165rv13, doi:10.1126/scitranslmed.3004404. open in new tab
2. Sanguinetti, M.; Posteraro, B.; Lass-Flörl, C. Antifungal drug resistance among Candida species: Mechanisms and clinical impact. Mycoses 2015, 58, 2-13, doi:10.1111/myc.12330. open in new tab
3. Perlin, D.S. Mechanisms of echinocandin antifungal drug resistance. Ann. N. Y. Acad. Sci. 2015, 1354, 1-11, doi:10.1111/nyas.12831. open in new tab
4. Odds, F.C.; Brown, A.J.P.; Gow, N.A.R. Antifungal agents: Mechanisms of action. Trends Microbiol. 2003, 11, 272-279, doi:10.1016/S0966-842X(03)00117-3. open in new tab
5. Pegu, R.; Borah, R.; Pratihar, S. Synthetic Compounds for Antifungal Chemotherapy. In Recent Trends in Antifungal Agents and Antifungal Therapy; open in new tab
6. Basak, A., Chakraborty, R., Mandal, S.M., Eds.; Springer: New Delhi, India, 2016; pp. 191-215, ISBN 978-81-322-2782-3.
7. Denning, D.W. Echinocandin antifungal drugs. Lancet 2003, 362, 1142-1151, doi:10.1016/S0140- 6736(03)14472-8. open in new tab
8. Aguilar-Zapata, D.; Petraitiene, R.; Petraitis, V. Echinocandins: The Expanding Antifungal Armamentarium. Clin. Infect. Dis. 2015, 61, S604-S611, doi:10.1093/cid/civ814. open in new tab
9. Perlin, D.S. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 2007, 10, 121-130, doi:10.1016/j.drup.2007.04.002. open in new tab
10. Cornely, O.A.; Bassetti, M.; Calandra, T.; Garbino, J.; Kullberg, B.J.; Lortholary, O.; Meersseman, W.; Akova, M.; Arendrup, M.C.; Arikan-Akdagli, S.; et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients. Clin. Microbiol. Infect. 2012, 18, 19-37, doi:10.1111/1469-0691.12039. open in new tab
11. Balkovec, J.M.; Hughes, D.L.; Masurekar, P.S.; Sable, C.A.; Schwartz, R.E.; Singh, S.B. Discovery and development of first in class antifungal caspofungin (CANCIDAS®)--a case study. Nat. Prod. Rep. 2014, 31, 15-34, doi:10.1039/c3np70070d. open in new tab
12. Joseph, J.M.; Jain, R.; Danziger, L.H. Micafungin: A New Echinocandin Antifungal. Pharmacotherapy 2007, 27, 53-67, doi:10.1592/phco.27.1.53. open in new tab
13. U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of MYCAMINE ® (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age;
14. Astellas Pharma US, Inc. Available online: https://www.astellas.com/us/news/4761 (accessed on 14 April 2020).
15. Roilides, E.; Carlesse, F.; Tawadrous, M.; Leister-Tebbe, H.; Conte, U.; Raber, S.; Swanson, R.; Yan, J.L.; Aram, J.A.; Queiroz-Telles, F.; et al. Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia. Pediatr. Infect. Dis. J. 2020, 39, 305-309, doi:10.1097/INF.0000000000002568. open in new tab
16. Roilides, E.; Carlesse, F.; Leister-Tebbe, H.; Conte, U.; Yan, J.L.; Liu, P.; Tawadrous, M.; Aram, J.A.; Queiroz- Telles, F. A Prospective, Open-label Study to Assess the Safety, Tolerability and Efficacy of Anidulafungin in the Treatment of Invasive Candidiasis in Children 2 to <18 Years of Age: Pediatr. Infect. Dis. J. 2019, 38, 275-279, doi:10.1097/INF.0000000000002237. open in new tab
17. Vazquez, J.A. Anidulafungin: A new echinocandin with a novel profile. Clin. Ther. 2005, 27, 657-673, doi:10.1016/j.clinthera.2005.06.010. open in new tab
18. Sanguinetti, M.; Posteraro, P.; Posteraro, B. Echinocandin Antifungal Drug Resistance in Candida Species: A Cause for Concern? Curr. Infect. Dis. Rep. 2010, 12, 437-443, doi:10.1007/s11908-010-0131-2. open in new tab
19. Cappelletty, D.; Eiselstein-McKitrick, K. The Echinocandins. Pharmacotherapy 2007, 27, 369-388, doi:10.1592/phco.27.3.369. open in new tab
20. Sucher, A.J.; Chahine, E.B.; Balcer, H.E. Echinocandins: The Newest Class of Antifungals. Ann. Pharmacother. 2009, 43, 1647-1657, doi:10.1345/aph.1M237. open in new tab
21. Douglas, C.M. Fungal b (1,3)-D-glucan synthesis. Med. Mycol. 2001, 39, 55-66, doi:10.1080/mmy.39.1.55.66. open in new tab
22. Qadota, H.; Python, C.P.; Inoue, S.B.; Arisawa, M.; Anraku, Y.; Zheng, Y.; Watanabe, T.; Levin, D.E.; Ohya, Y. Identification of yeast Rho1p GTPase as a regulatory subunit of 1,3-beta-glucan synthase. Science 1996, 272, 279-281, doi:10.1126/science.272.5259.279. open in new tab
23. Suwunnakorn, S.; Wakabayashi, H.; Kordalewska, M.; Perlin, D.S.; Rustchenko, E. FKS2 and FKS3 Genes of Opportunistic Human Pathogen Candida albicans Influence Echinocandin Susceptibility. Antimicrob. Agents Chemother. 2018, 62, e02299-17, doi:10.1128/AAC.02299-17. open in new tab
24. Arendrup, M.C.; Cuenca-Estrella, M.; Lass-Flörl, C.; Hope, W. EUCAST technical note on the EUCAST definitive document EDef 7.2: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)*. Clin. Microbiol. Infect. 2012, 18, E246-E247, doi:10.1111/j.1469-0691.2012.03880.x. open in new tab
25. European Committee on Antimicrobial Susceptibility Testing Clinical Breakpoints for Antifungals. Available online: http://www.eucast.org/astoffungi/clinicalbreakpointsforantifungals/ (accessed on 13 February 2020). open in new tab
26. Arendrup, M.C.; Jørgensen, K.M.; Hare, R.K.; Cuenca-Estrella, M.; Zaragoza, O. EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates. Antimicrob. Agents Chemother. 2019, 63, e00659-19, doi:10.1128/AAC.00659-19. open in new tab
27. Cleveland, A.A.; Farley, M.M.; Harrison, L.H.; Stein, B.; Hollick, R.; Lockhart, S.R.; Magill, S.S.; Derado, G.; Park, B.J.; Chiller, T.M. Changes in Incidence and Antifungal Drug Resistance in Candidemia: Results From Population-Based Laboratory Surveillance in Atlanta and Baltimore, 2008-2011. Clin. Infect. Dis. 2012, 55, 1352-1361, doi:10.1093/cid/cis697. open in new tab
28. Chowdhary, A.; Sharma, C.; Meis, J.F. Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017, 13, e1006290, doi:10.1371/journal.ppat.1006290. open in new tab
29. Chowdhary, A.; Voss, A.; Meis, J.F. Multidrug-resistant Candida auris: 'new kid on the block' in hospital- associated infections? J. Hosp. Infect. 2016, 94, 209-212, doi:10.1016/j.jhin.2016.08.004. open in new tab
30. Walker, L.A.; Gow, N.A.R.; Munro, C.A. Fungal echinocandin resistance. Fungal Genet. Biol. 2010, 47, 117- 126, doi:10.1016/j.fgb.2009.09.003. open in new tab
31. Staab, J.F.; Kahn, J.N.; Marr, K.A. Differential Aspergillus lentulus Echinocandin Susceptibilities Are Fksp Independent. Antimicrob. Agents Chemother. 2010, 54, 4992-4998, doi:10.1128/AAC.00774-10. open in new tab
32. Perlin, D.S. Current perspectives on echinocandin class drugs. Future Microbiol. 2011, 6, 441-457, doi:10.2217/fmb.11.19. open in new tab
33. Walker, L.A.; Lee, K.K.; Munro, C.A.; Gow, N.A.R. Caspofungin Treatment of Aspergillus fumigatus Results in ChsG-Dependent Upregulation of Chitin Synthesis and the Formation of Chitin-Rich Microcolonies. Antimicrob. Agents Chemother. 2015, 59, 5932-5941, doi:10.1128/AAC.00862-15. open in new tab
34. Ikeda, R.; Sugita, T.; Jacobson, E.S.; Shinoda, T. Effects of Melanin upon Susceptibility of Cryptococcus to Antifungals. Microbiol. Immunol. 2003, 47, 271-277, doi:10.1111/j.1348-0421.2003.tb03395.x. open in new tab
35. Maligie, M.A.; Selitrennikoff, C.P. Cryptococcus neoformans Resistance to Echinocandins: (1,3)β-Glucan Synthase Activity Is Sensitive to Echinocandins. Antimicrob. Agents Chemother. 2005, 49, 2851-2856, doi:10.1128/AAC.49.7.2851-2856.2005. open in new tab
36. McBride, J.A.; Gauthier, G.M.; Klein, B.S. Clinical manifestations and treatment of blastomycosis. Clin. Chest Med. 2017, 38, 435-449, doi:10.1016/j.ccm.2017.04.006. open in new tab
37. Anderson, T. Echinocandin Antifungals. In Drug Dosing in Obesity: Volume I: Antimicrobials; open in new tab
38. Zaidi, S.T.R., Roberts, J.A., Eds.; Springer: Cham, Switzerland, 2016; pp. 97-107, ISBN 978-3-319-44034-7.
39. Iii, G.R.T.; Barker, B.M.; Wiederhold, N.P. Large-Scale Evaluation of In Vitro Amphotericin B, Triazole, and Echinocandin Activity against Coccidioides Species from U.S. Institutions. Antimicrob. Agents Chemother. 2017, 61, e02634-16, doi:10.1128/AAC.02634-16. open in new tab
40. González, G.M.; Tijerina, R.; Najvar, L.K.; Bocanegra, R.; Luther, M.; Rinaldi, M.G.; Graybill, J.R. Correlation between Antifungal Susceptibilities of Coccidioides immitis In Vitro and Antifungal Treatment with Caspofungin in a Mouse Model. Antimicrob. Agents Chemother. 2001, 45, 1854-1859, doi:10.1128/AAC.45.6.1854-1859.2001. open in new tab
41. Castanheira, M.; Messer, S.A.; Jones, R.N.; Farrell, D.J.; Pfaller, M.A. Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. Int. J. Antimicrob. Agents 2014, 44, 320-326, doi:10.1016/j.ijantimicag.2014.06.007. open in new tab
42. Pfaller, M.A.; Carvalhaes, C.; Messer, S.A.; Rhomberg, P.R.; Castanheira, M. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018). Antimicrob. Agents Chemother. 2020, 64, e00099-20, doi:10.1128/AAC.00099-20. open in new tab
43. Martos, A.I.; Romero, A.; González, M.T.; González, A.; Serrano, C.; Castro, C.; Pemán, J.; Cantón, E.; Martín-Mazuelos, E. Evaluation of the Etest method for susceptibility testing of Aspergillus spp. and Fusarium spp. to three echinocandins. Med. Mycol. 2010, 48, 858-861, doi:10.3109/13693781003586943. open in new tab
44. Perdomo, H.; Sutton, D.A.; García, D.; Fothergill, A.W.; Cano, J.; Gené, J.; Summerbell, R.C.; Rinaldi, M.G.; Guarro, J. Spectrum of Clinically Relevant Acremonium Species in the United States. J. Clin. Microbiol. 2011, 49, 243-256, doi:10.1128/JCM.00793-10. open in new tab
45. da Cunha, K.C.; Sutton, D.A.; Fothergill, A.W.; Gené, J.; Cano, J.; Madrid, H.; de Hoog, S.; Crous, P.W.; Guarro, J. In vitro antifungal susceptibility and molecular identity of 99 clinical isolates of the opportunistic fungal genus Curvularia. Diagn. Microbiol. Infect. Dis. 2013, 76, 168-174, doi:10.1016/j.diagmicrobio.2013.02.034. open in new tab
46. Singh, J.; Rimek, D.; Kappe, R. In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38-A microdilution method. Mycoses 2005, 48, 246-250, doi:10.1111/j.1439- 0507.2005.01132.x. open in new tab
47. Sandoval-Denis, M.; Sutton, D.A.; Cano-Lira, J.F.; Gene, J.; Fothergill, A.W.; Wiederhold, N.P.; Guarro, J. Phylogeny of the Clinically Relevant Species of the Emerging Fungus Trichoderma and Their Antifungal Susceptibilities. J. Clin. Microbiol. 2014, 52, 2112-2125, doi:10.1128/JCM.00429-14. open in new tab
48. Song, J.C.; Stevens, D.A. Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes. Crit. Rev. Microbiol. 2016, 42, 813-846, doi:10.3109/1040841X.2015.1068271. open in new tab
49. Stevens, D.A.; Espiritu, M.; Parmar, R. Paradoxical Effect of Caspofungin: Reduced Activity against Candida albicans at High Drug Concentrations. Antimicrob. Agents Chemother. 2004, 48, 3407-3411, doi:10.1128/AAC.48.9.3407-3411.2004. open in new tab
50. Chamilos, G.; Lewis, R.E.; Albert, N.; Kontoyiannis, D.P. Paradoxical Effect of Echinocandins across Candida Species In Vitro: Evidence for Echinocandin-Specific and Candida Species-Related Differences. Antimicrob. Agents Chemother. 2007, 51, 2257-2259, doi:10.1128/AAC.00095-07. open in new tab
51. Stevens, D.A.; White, T.C.; Perlin, D.S.; Selitrennikoff, C.P. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn. Microbiol. Infect. Dis. 2005, 51, 173-178, doi:10.1016/j.diagmicrobio.2004.10.006. open in new tab
52. Stevens, D.A.; Ichinomiya, M.; Koshi, Y.; Horiuchi, H. Escape of Candida from Caspofungin Inhibition at Concentrations above the MIC (Paradoxical Effect) Accomplished by Increased Cell Wall Chitin; Evidence for β-1,6-Glucan Synthesis Inhibition by Caspofungin. Antimicrob. Agents Chemother. 2006, 50, 3160-3161, doi:10.1128/AAC.00563-06. open in new tab
53. Wagener, J.; Loiko, V. Recent Insights into the Paradoxical Effect of Echinocandins. J. Fungi (Basel) 2018, 4, 5, doi:10.3390/jof4010005. open in new tab
54. Juvvadi, P.R.; Muñoz, A.; Lamoth, F.; Soderblom, E.J.; Moseley, M.A.; Read, N.D.; Steinbach, W.J. Calcium- Mediated Induction of Paradoxical Growth following Caspofungin Treatment Is Associated with Calcineurin Activation and Phosphorylation in Aspergillus fumigatus. Antimicrob. Agents Chemother. 2015, 59, 4946-4955, doi:10.1128/AAC.00263-15. open in new tab
55. Klont, R.R.; Mennink-Kersten, M.A.S.H.; Ruegebrink, D.; Rijs, A.J.M.M.; Blijlevens, N.M.A.; Donnelly, J.P.; Verweij, P.E. Paradoxical Increase in Circulating Aspergillus Antigen during Treatment with Caspofungin in a Patient with Pulmonary Aspergillosis. Clin. Infect. Dis. 2006, 43, e23-e25, doi:10.1086/505603. open in new tab
56. Fortún, J.; Martín-Dávila, P.; Montejo, M.; Muñoz, P.; Cisneros, J.; Ramos, A.; Aragón, C.; Blanes, M.; Juan, R.S.; Gavaldá, J.; et al. Prophylaxis With Caspofungin for Invasive Fungal Infections in High-Risk Liver Transplant Recipients. Transplantation 2009, 87, 424-435, doi:10.1097/TP.0b013e3181932e76. open in new tab
57. Hoffman, J.A.; Walsh, T.J. Echinocandins in Children. Pediatr. Infect. Dis. J. 2011, 30, 508-509, doi:10.1097/INF.0b013e31821b95e2. open in new tab
58. Perea, S.; Gonzalez, G.; Fothergill, A.W.; Kirkpatrick, W.R.; Rinaldi, M.G.; Patterson, T.F. In Vitro Interaction of Caspofungin Acetate with Voriconazole against Clinical Isolates of Aspergillus spp. Antimicrob. Agents Chemother. 2002, 46, 3039-3041, doi:10.1128/AAC.46.9.3039-3041.2002. open in new tab
59. Petraitis, V.; Petraitiene, R.; Sarafandi, A.A.; Kelaher, A.M.; Lyman, C.A.; Casler, H.E.; Sein, T.; Groll, A.H.; Bacher, J.; Avila, N.A.; et al. Combination Therapy in Treatment of Experimental Pulmonary Aspergillosis: Synergistic Interaction between an Antifungal Triazole and an Echinocandin. J. Infect. Dis. 2003, 187, 1834- 1843, doi:10.1086/375420. open in new tab
60. Calvo, E.; Pastor, F.J.; Salas, V.; Mayayo, E.; Guarro, J. Combined Therapy of Voriconazole and Anidulafungin in Murine Infections by Aspergillus flavus. Mycopathologia 2012, 173, 251-257, doi:10.1007/s11046-011-9507-6. open in new tab
61. Marr, K.A.; Schlamm, H.T.; Herbrecht, R.; Rottinghaus, S.T.; Bow, E.J.; Cornely, O.A.; Heinz, W.J.; Jagannatha, S.; Koh, L.P.; Kontoyiannis, D.P.; et al. Combination Antifungal Therapy for Invasive Aspergillosis: A Randomized Trial. Ann. Intern. Med. 2015, 162, 81-89, doi:10.7326/M13-2508. open in new tab
62. Marr, K.A.; Boeckh, M.; Carter, R.A.; Kim, H.W.; Corey, L. Combination antifungal therapy for invasive aspergillosis. Clin. Infect. Dis. 2004, 39, 797-802, doi:10.1086/423380. open in new tab
63. Kirkpatrick, W.R.; Perea, S.; Coco, B.J.; Patterson, T.F. Efficacy of Caspofungin Alone and in Combination with Voriconazole in a Guinea Pig Model of Invasive Aspergillosis. Antimicrob. Agents Chemother. 2002, 46, 2564-2568, doi:10.1128/AAC.46.8.2564-2568.2002. open in new tab
64. Raad, I.I.; Zakhem, A.E.; Helou, G.E.; Jiang, Y.; Kontoyiannis, D.P.; Hachem, R. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int. J. Antimicrob. Agents 2015, 45, 283-288, doi:10.1016/j.ijantimicag.2014.08.012. open in new tab
65. Perlin, D.S.; Hope, W.W. Echinocandins. In Aspergillosis: From Diagnosis to Prevention; open in new tab
66. Comarú Pasqualotto, A., Ed.; Springer: Dordrecht, The Netherlands, 2010; pp. 263-279, ISBN 978-90-481-2408-4.
67. Kartsonis, N.A.; Nielsen, J.; Douglas, C.M. Caspofungin: The first in a new class of antifungal agents. Drug Resist. Updat. 2003, 6, 197-218, doi:10.1016/S1368-7646(03)00064-5. open in new tab
68. Grover, N.D. Echinocandins: A ray of hope in antifungal drug therapy. Indian J. Pharmacol. 2010, 42, 9-11, doi:10.4103/0253-7613.62396. open in new tab
69. Wiederhold, N.P.; Lewis, J.S. The echinocandin micafungin: A review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin. Pharmacother. 2007, 8, 1155-1166, doi:10.1517/14656566.8.8.1155. open in new tab
70. Park, S.; Kelly, R.; Kahn, J.N.; Robles, J.; Hsu, M.-J.; Register, E.; Li, W.; Vyas, V.; Fan, H.; Abruzzo, G.; et al. Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates. Antimicrob. Agents Chemother. 2005, 49, 3264-3273, doi:10.1128/AAC.49.8.3264-3273.2005. open in new tab
71. Grossman, N.T.; Chiller, T.M.; Lockhart, S.R. Epidemiology of echinocandin resistance in Candida. Curr. Fungal Infect. Rep. 2014, 8, 243-248, doi:10.1007/s12281-014-0209-7. open in new tab
72. Castanheira, M.; Woosley, L.N.; Diekema, D.J.; Messer, S.A.; Jones, R.N.; Pfaller, M.A. Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains. Antimicrob. Agents Chemother. 2010, 54, 2655-2659, doi:10.1128/AAC.01711-09. open in new tab
73. Alexander, B.D.; Johnson, M.D.; Pfeiffer, C.D.; Jiménez-Ortigosa, C.; Catania, J.; Booker, R.; Castanheira, M.; Messer, S.A.; Perlin, D.S.; Pfaller, M.A. Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations. Clin. Infect. Dis. 2013, 56, 1724-1732, doi:10.1093/cid/cit136. open in new tab
74. Hakki, M.; Staab, J.F.; Marr, K.A. Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy. Antimicrob. Agents Chemother. 2006, 50, 2522-2524, doi:10.1128/AAC.00148- 06. open in new tab
75. Kahn, J.N.; Garcia-Effron, G.; Hsu, M.-J.; Park, S.; Marr, K.A.; Perlin, D.S. Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase. Antimicrob. Agents Chemother. 2007, 51, 1876-1878, doi:10.1128/AAC.00067-07. open in new tab
76. Forastiero, A.; Garcia-Gil, V.; Rivero-Menendez, O.; Garcia-Rubio, R.; Monteiro, M.C.; Alastruey-Izquierdo, A.; Jordan, R.; Agorio, I.; Mellado, E. Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy. Antimicrob. Agents Chemother. 2015, 59, 6975-6982, doi:10.1128/AAC.01005- 15. open in new tab
77. Spellberg, B.J.; Filler, S.G.; Edwards, J.E. Current Treatment Strategies for Disseminated Candidiasis. Clin. Infect. Dis. 2006, 42, 244-251, doi:10.1086/499057. open in new tab
78. Infection Prevention and Control for Candida auris | Candida auris | Fungal Diseases | CDC. Available online: https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html (accessed on 8 March 2020). open in new tab
79. Satoh, K.; Makimura, K.; Hasumi, Y.; Nishiyama, Y.; Uchida, K.; Yamaguchi, H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol. Immunol. 2009, 53, 41-44, doi:10.1111/j.1348-0421.2008.00083.x. open in new tab
80. Lee, W.G.; Shin, J.H.; Uh, Y.; Kang, M.G.; Kim, S.H.; Park, K.H.; Jang, H.-C. First three reported cases of nosocomial fungemia caused by Candida auris. J. Clin. Microbiol. 2011, 49, 3139-3142, doi:10.1128/JCM.00319-11. open in new tab
81. Chowdhary, A.; Sharma, C.; Duggal, S.; Agarwal, K.; Prakash, A.; Singh, P.K.; Jain, S.; Kathuria, S.; Randhawa, H.S.; Hagen, F.; et al. New Clonal Strain of Candida auris, Delhi, India. Emerg. Infect. Dis. 2013, 19, 1670-1673, doi:10.3201/eid1910.130393. open in new tab
82. Schelenz, S.; Hagen, F.; Rhodes, J.L.; Abdolrasouli, A.; Chowdhary, A.; Hall, A.; Ryan, L.; Shackleton, J.; Trimlett, R.; Meis, J.F.; et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob. Resist. Infect. Control. 2016, 5, 35, doi:10.1186/s13756-016-0132-5. open in new tab
83. Calvo, B.; Melo, A.S.A.; Perozo-Mena, A.; Hernandez, M.; Francisco, E.C.; Hagen, F.; Meis, J.F.; Colombo, A.L. First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. J. Infect. 2016, 73, 369-374, doi:10.1016/j.jinf.2016.07.008. open in new tab
84. Sears, D.; Schwartz, B.S. Candida auris: An emerging multidrug-resistant pathogen. Int. J. Infect. Dis. 2017, 63, 95-98, doi:10.1016/j.ijid.2017.08.017. open in new tab
85. Al Maani, A.; Paul, H.; Al-Rashdi, A.; Al Wahaibi, A.; Al-Jardani, A.; Al Abri, A.M.A.; AlBalushi, M.A.H.; Al Abri, S.; Al Reesi, M.; Al Maqbali, A.; et al. Ongoing Challenges with Healthcare-Associated Candida auris Outbreaks in Oman. J. Fungi (Basel) 2019, 5, 101, doi:10.3390/jof5040101. open in new tab
86. Chowdhary, A.; Prakash, A.; Sharma, C.; Kordalewska, M.; Kumar, A.; Sarma, S.; Tarai, B.; Singh, A.; Upadhyaya, G.; Upadhyay, S.; et al. A multicentre study of antifungal susceptibility patterns among 350 open in new tab
87. Candida auris isolates (2009-17) in India: Role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J. Antimicrob. Chemother. 2018, 73, 891-899, doi:10.1093/jac/dkx480. 83. Identification of Candida auris | Candida auris | Fungal Diseases | CDC. Available online: https://www.cdc.gov/fungal/candida-auris/recommendations.html (accessed on 8 March 2020). open in new tab
88. Beyda, N.D.; John, J.; Kilic, A.; Alam, M.J.; Lasco, T.M.; Garey, K.W. FKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia. Clin. Infect. Dis. 2014, 59, 819-825, doi:10.1093/cid/ciu407. open in new tab
89. Fekkar, A.; Dannaoui, E.; Meyer, I.; Imbert, S.; Brossas, J.Y.; Uzunov, M.; Mellon, G.; Nguyen, S.; Guiller, E.; Caumes, E.; et al. Emergence of echinocandin-resistant Candida spp. in a hospital setting: A consequence of 10 years of increasing use of antifungal therapy? Eur. J. Clin. Microbiol. Infect. Dis. 2014, 33, 1489-1496, doi:10.1007/s10096-014-2096-9. open in new tab
90. Shields, R.K.; Nguyen, M.H.; Clancy, C.J. Clinical perspectives on echinocandin resistance among Candida species. Curr. Opin. Infect. Dis. 2015, 28, 514-522, doi:10.1097/QCO.0000000000000215. open in new tab
91. Ruggero, M.A.; Topal, J.E. Development of echinocandin-resistant Candida albicans candidemia following brief prophylactic exposure to micafungin therapy. Transpl. Infect. Dis. 2014, 16, 469-472, doi:10.1111/tid.12230. open in new tab
92. Bizerra, F.C.; Jimenez-Ortigosa, C.; Souza, A.C.R.; Breda, G.L.; Queiroz-Telles, F.; Perlin, D.S.; Colombo, A.L. Breakthrough Candidemia Due to Multidrug-Resistant Candida glabrata during Prophylaxis with a Low Dose of Micafungin. Antimicrob. Agents Chemother. 2014, 58, 2438-2440, doi:10.1128/AAC.02189-13. open in new tab
93. Mitchell, K.F.; Taff, H.T.; Cuevas, M.A.; Reinicke, E.L.; Sanchez, H.; Andes, D.R. Role of Matrix β-1,3 Glucan in Antifungal Resistance of Non-albicans Candida Biofilms. Antimicrob. Agents Chemother. 2013, 57, 1918- 1920, doi:10.1128/AAC.02378-12. open in new tab
94. Perlin, D.S. Echinocandin Resistance in Candida. Clin. Infect. Dis. 2015, 61, S612-S617, doi:10.1093/cid/civ791. open in new tab
95. Cowen, L.E.; Steinbach, W.J. Stress, Drugs, and Evolution: The Role of Cellular Signaling in Fungal Drug Resistance. Eukaryot. Cell 2008, 7, 747-764, doi:10.1128/EC.00041-08. open in new tab
96. Perlin, D.S. Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management. Drugs 2014, 74, 1573-1585, doi:10.1007/s40265-014-0286-5. open in new tab
97. Shields, R.K.; Nguyen, M.H.; Press, E.G.; Cumbie, R.; Driscoll, E.; Pasculle, A.W.; Clancy, C.J. Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection. Antimicrob. Agents Chemother. 2015, 59, 7465-7470, doi:10.1128/AAC.01973-15. open in new tab
98. Ben-Ami, R.; Garcia-Effron, G.; Lewis, R.E.; Gamarra, S.; Leventakos, K.; Perlin, D.S.; Kontoyiannis, D.P. Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance. J. Infect. Dis. 2011, 204, 626-635, doi:10.1093/infdis/jir351. open in new tab
99. Gardiner, R.E.; Souteropoulos, P.; Park, S.; Perlin, D.S. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med. Mycol. 2005, 43, S299-S305, doi:10.1080/13693780400029023. open in new tab
100. Pfaller, M.A.; Diekema, D.J.; Messer, S.A.; Hollis, R.J.; Jones, R.N. In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates. Antimicrob. Agents Chemother. 2003, 47, 1068-1071, doi:10.1128/AAC.47.3.1068-1071.2003. open in new tab
101. Pfaller, M.A.; Messer, S.A.; Boyken, L.; Rice, C.; Tendolkar, S.; Hollis, R.J.; Diekema, D.J. Caspofungin Activity against Clinical Isolates of Fluconazole-Resistant Candida. J. Clin. Microbiol. 2003, 41, 5729-5731, doi:10.1128/JCM.41.12.5729-5731.2003. open in new tab
102. Niimi, K.; Maki, K.; Ikeda, F.; Holmes, A.R.; Lamping, E.; Niimi, M.; Monk, B.C.; Cannon, R.D. Overexpression of Candida albicans CDR1, CDR2, or MDR1 Does Not Produce Significant Changes in Echinocandin Susceptibility. Antimicrob. Agents Chemother. 2006, 50, 1148-1155, doi:10.1128/AAC.50.4.1148- 1155.2006. open in new tab
103. Lesage, G.; Bussey, H. Cell Wall Assembly in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 2006, 70, 317-343, doi:10.1128/MMBR.00038-05. open in new tab
104. Chatterjee, S.; Alampalli, S.V.; Nageshan, R.K.; Chettiar, S.T.; Joshi, S.; Tatu, U.S. Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genomics 2015, 16, 686, doi:10.1186/s12864-015-1863-z. open in new tab
105. Krishnan, B.R.; James, K.D.; Polowy, K.; Bryant, B.J.; Vaidya, A.; Smith, S.; Laudeman, C.P. CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility. J. Antibiot. 2017, 70, 130-135, doi:10.1038/ja.2016.89. open in new tab
106. Pfaller, M.A.; Messer, S.A.; Rhomberg, P.R.; Jones, R.N.; Castanheira, M. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin-and azole-resistant isolates. J. Antimicrob. Chemother. 2016, 71, 2868-2873, doi:10.1093/jac/dkw214. open in new tab
107. Ong, V.; Hough, G.; Schlosser, M.; Bartizal, K.; Balkovec, J.M.; James, K.D.; Krishnan, B.R. Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin. Antimicrob. Agents Chemother. 2016, 60, 6872-6879, doi:10.1128/AAC.00701-16. open in new tab
108. Pfaller, M.A.; Messer, S.A.; Rhomberg, P.R.; Castanheira, M. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program. Int. J. Antimicrob. Agents 2017, 50, 352-358, doi:10.1016/j.ijantimicag.2017.03.028. open in new tab
109. Pfaller, M.A.; Messer, S.A.; Rhomberg, P.R.; Castanheira, M. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program. Antimicrob. Agents Chemother. 2017, 61, e02045-16, doi:10.1128/AAC.02045-16. open in new tab
110. Boikov, D.A.; Locke, J.B.; James, K.D.; Bartizal, K.; Sobel, J.D. In vitro activity of the novel echinocandin CD101 at pH 7 and 4 against Candida spp. isolates from patients with vulvovaginal candidiasis. J. Antimicrob. Chemother. 2017, 72, 1355-1358, doi:10.1093/jac/dkx008. open in new tab
111. Arendrup, M.C.; Meletiadis, J.; Zaragoza, O.; Jørgensen, K.M.; Marcos-Zambrano, L.J.; Kanioura, L.; Cuenca-Estrella, M.; Mouton, J.W.; Guinea, J. Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method. Clin. Microbiol. Infect. 2018, 24, 1200-1204, doi:10.1016/j.cmi.2018.02.021. open in new tab
112. Chandra, J.; Ghannoum, M.A. CD101, a Novel Echinocandin, Possesses Potent Antibiofilm Activity against Early and Mature Candida albicans Biofilms. Antimicrob. Agents Chemother. 2017, 62, e01750-17, doi:10.1128/AAC.01750-17. open in new tab
113. Locke, J.B.; Almaguer, A.L.; Zuill, D.E.; Bartizal, K. Characterization of In Vitro Resistance Development to the Novel Echinocandin CD101 in Candida Species. Antimicrob. Agents Chemother. 2016, 60, 6100-6107, doi:10.1128/AAC.00620-16. open in new tab
114. Berkow, E.L.; Lockhart, S.R. Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris. Diagn. Microbiol. Infect. Dis. 2018, 90, 196-197, doi:10.1016/j.diagmicrobio.2017.10.021. open in new tab
115. Hager, C.L.; Larkin, E.L.; Long, L.A.; Ghannoum, M.A. Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J. Antimicrob. Chemother. 2018, 73, 2085-2088, doi:10.1093/jac/dky153. open in new tab
116. Wring, S.A.; Randolph, R.; Park, S.; Abruzzo, G.; Chen, Q.; Flattery, A.; Garrett, G.; Peel, M.; Outcalt, R.; Powell, K.; et al. Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis. Antimicrob. Agents Chemother. 2017, 61, e02068-16, doi:10.1128/AAC.02068-16. open in new tab
117. Ghannoum, M.; Long, L.; Larkin, E.L.; Isham, N.; Sherif, R.; Borroto-Esoda, K.; Barat, S.; Angulo, D. Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis. Antimicrob. Agents Chemother. 2018, 62, e00244- 18, doi:10.1128/AAC.00244-18. open in new tab
118. Scorneaux, B.; Angulo, D.; Borroto-Esoda, K.; Ghannoum, M.; Peel, M.; Wring, S. SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies. Antimicrob. Agents Chemother. 2017, 61, e01961-16, doi:10.1128/AAC.01961-16. open in new tab
119. Nunnally, N.S.; Etienne, K.A.; Angulo, D.; Lockhart, S.R.; Berkow, E.L. In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations. Antimicrob. Agents Chemother. 2019, 63, e01692-19, doi:10.1128/AAC.01692-19. open in new tab
120. Jiménez-Ortigosa, C.; Paderu, P.; Motyl, M.R.; Perlin, D.S. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida Species and Aspergillus species isolates. Antimicrob. Agents Chemother. 2014, 58, 1248-1251, doi:10.1128/AAC.02145-13. open in new tab
121. Berkow, E.L.; Angulo, D.; Lockhart, S.R. In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris. Antimicrob. Agents Chemother. 2017, 61, e00435-17, doi:10.1128/AAC.00435-17. open in new tab
122. Cornely, O.A.; Sidhu, M.; Odeyemi, I.; van Engen, A.K.; van der Waal, J.M.; Schoeman, O. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr. Med. Res. Opin. 2008, 24, 1743-1753, doi:10.1185/03007990802124889. open in new tab
123. Bruynesteyn, K.; Gant, V.; McKenzie, C.; Pagliuca, T.; Poynton, C.; Kumar, R.N.; Jansen, J.P. A cost- effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur. J. Haematol. 2007, 78, 532-539, doi:10.1111/j.1600-0609.2007.00850.x. open in new tab
124. Neoh, C.F.; Liew, D.; Slavin, M.; Marriott, D.; Chen, S.C.-A.; Morrissey, O.; Stewart, K.; Kong, D.C.M. Cost- effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. J. Antimicrob. Chemother. 2011, 66, 1906-1915, doi:10.1093/jac/dkr186. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). open in new tab

show (124) hide

Verified by:

Gdańsk University of Technology